Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Investigation

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI78450PMID 25751145PMCID PMC4409022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proof of principle for epitope-focused vaccine design

  2014cited by this paper
• Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

  2013cited by this paper
• Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

  2013cited by this paper
• Burden of respiratory syncytial virus infection in young children.

  2012cited by this paper
• Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats

  2012cited by this paper
• An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

  2012cited by this paper
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  2012cited by this paper
• The burgeoning burden of respiratory syncytial virus among children.

  2012cited by this paper
• Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

  2011influential reference
• Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

  2011cited by this paper
• Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

  2011cited by this paper
• Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

  2010cited by this paper
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  2010cited by this paper
• Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

  2010cited by this paper
• Structural basis of respiratory syncytial virus neutralization by motavizumab

  2010cited by this paper
• Update on 2009 H1N1 influenza vaccine issues

  2009cited by this paper
• Interaction of the Hepatitis B Core Antigen and the Innate Immune System1

  2009cited by this paper
• Use of hepadnavirus core proteins as vaccine platforms

  2009cited by this paper
• Reducing RSV hospitalizations AAP modifies recommendations for use of palivizumab in high-risk infants, young children

  2009cited by this paper
• Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

  2009cited by this paper
• The burden of respiratory syncytial virus infection in young children.

  2009cited by this paper
• Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres

  2009cited by this paper
• Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.

  2008cited by this paper
• Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

  2007influential reference
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Early Antibodies Specific for the Neutralizing Epitope on the Receptor Binding Subunit of the Lymphocytic Choriomeningitis Virus Glycoprotein Fail To Neutralize the Virus

  2007cited by this paper
• Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis

  2007cited by this paper
• Combinatorial Approach to Hepadnavirus-Like Particle Vaccine Design

  2005cited by this paper
• Age related differences in humoral immune response to respiratory syncytial virus infection in adults

  2004cited by this paper
• The crystal structure of the human hepatitis B virus capsid.

  1999cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein

  1998cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens.

  1998cited by this paper
• Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein.

  1998cited by this paper
• Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy

  1997cited by this paper
• The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype

  1997cited by this paper
• Role of B cells in antigen presentation of the hepatitis B core.

  1997cited by this paper
• Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

  1993cited by this paper
• Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

  1992cited by this paper
• Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

  1989influential reference
• Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

  1969cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969influential reference
• An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

  1969cited by this paper

• Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

  2026cites this paper
• A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis

  2025cites this paper
• A Lyophilizable Nanoparticle Anthrax Vaccine Targeting the Loop-Neutralizing Determinant in Protective Antigen from Bacillus anthracis

  2025cites this paper
• Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus

  2024cites this paper
• A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F

  2023cites this paper
• Self-assembled multiepitope nanovaccine based on NoV P particles induces effective and lasting protection against H3N2 influenza virus

  2023cites this paper
• Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

  2023cites this paper
• Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection

  2023cites this paper
• HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice

  2022cites this paper
• Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals

  2022cites this paper
• Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection

  2021cites this paper
• Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response

  2021cites this paper
• Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond

  2021cites this paper
• Innate Type 2 Responses to Respiratory Syncytial Virus Infection

  2020cites this paper
• Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice

  2020cites this paper
• Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy

  2020cites this paper
• Nanoparticle vaccines against respiratory syncytial virus.

  2020cites this paper
• Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections

  2019cites this paper
• Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance

  2019cites this paper
• Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia

  2018cites this paper
• Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus

  2018cites this paper
• Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein

  2017cites this paper
• Molecular evolution of the fusion protein (F) gene in human respiratory syncytial virus subgroup B.

  2017cites this paper
• A single intranasal administration of virus‐like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus

  2017cites this paper
• Respiratory syncytial virus infection of newborn CX3CR1-deficient mice induces a pathogenic pulmonary innate immune response.

  2017cites this paper
• Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection

  2017cites this paper
• Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.

  2017cites this paper
• RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

  2017cites this paper
• Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus

  2016cites this paper
• The true story and advantages of the famous Hepatitis B virus core particles: Outlook 2016

  2016cites this paper
• Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development

  2016cites this paper
• Recent advances in the development of subunit-based RSV vaccines

  2016cites this paper
• Antibody-guided vaccine design: identification of protective epitopes.

  2016cites this paper
• Virus-Like Particle and Nanoparticle Vaccines

  2016cites this paper
• Molecular evolution of the fusion protein gene in human respiratory syncytial virus subgroup A.

  2016cites this paper
• Vaccination against Viruses

  2016cites this paper
• Approved Antiviral Drugs over the Past 50 Years

  2016cites this paper
• The promise and challenge of epitope-focused vaccines

  2016cites this paper
• Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein

  2016cites this paper
• The changing landscape of respiratory syncytial virus.

  2015cites this paper
• respiratory syncytial virus disease

  2015cites this paper
• Chronic hepatitis B: A wave of new therapies on the horizon.

  2015cites this paper
• Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

  2015cites this paper